M
Makiko Shimizu
Researcher at Showa Pharmaceutical University
Publications - 215
Citations - 3512
Makiko Shimizu is an academic researcher from Showa Pharmaceutical University. The author has contributed to research in topics: Physiologically based pharmacokinetic modelling & Pharmacokinetics. The author has an hindex of 28, co-authored 195 publications receiving 2805 citations. Previous affiliations of Makiko Shimizu include Vanderbilt University & Central Institute for Experimental Animals.
Papers
More filters
Journal ArticleDOI
Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population
Genta Sawada,Genta Sawada,Atsushi Niida,Ryutaro Uchi,Hidenari Hirata,Teppei Shimamura,Yutaka Suzuki,Yuichi Shiraishi,Kenichi Chiba,Seiya Imoto,Yusuke Takahashi,Yusuke Takahashi,Takeshi Iwaya,Tomoya Sudo,Tomoatsu Hayashi,Hiroki Takai,Yoshihiro Kawasaki,Takashi Matsukawa,Hidetoshi Eguchi,Keishi Sugimachi,Fumiaki Tanaka,Hiromichi Suzuki,Ken Yamamoto,Hideshi Ishii,Makiko Shimizu,Hiroshi Yamazaki,Makoto Yamazaki,Yuji Tachimori,Yoshiaki Kajiyama,Shoji Natsugoe,Hiromasa Fujita,Ken-ichi Mafune,Yoichi Tanaka,David P. Kelsell,Claire A. Scott,Shoji Tsuji,Shinichi Yachida,Tatsuhiro Shibata,Sumio Sugano,Yuichiro Doki,Tetsu Akiyama,Hiroyuki Aburatani,Seishi Ogawa,Satoru Miyano,Masaki Mori,Koshi Mimori +45 more
TL;DR: A large-scale genomic analysis of ESCCs from patients in Japan determined the mutational landscape of this cancer and associated environmental and genetic factors with base substitution patterns of somatic mutations and provide a registry of genes and pathways that are disrupted in ES CCs.
Journal ArticleDOI
Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes
TL;DR: It is suggested that 4-hydroxylation to N-oxidation metabolic ratios in liver microsomes from the wild-type CYP2C19*1/*1 individuals were lower than those observed in other genotypes and that 3-hydroxyvoriconazoles formation may become an important pathway for voriconazole metabolism in individuals with poor CYP1C19 catalytic function.
Journal ArticleDOI
Eubacterium limosum ameliorates experimental colitis and metabolite of microbe attenuates colonic inflammatory action with increase of mucosal integrity.
Osamu Kanauchi,Masanobu Fukuda,Yoshiaki Matsumoto,Shino Ishii,Toyokazu Ozawa,Makiko Shimizu,Keiichi Mitsuyama,Akira Andoh +7 more
TL;DR: In part, the metabolite of E. limosum, butyrate, increases mucosal integrity and shows anti-inflammatory action modulation of mucosal defense system via TLR4.
Journal ArticleDOI
Sulfation of bisphenol A abolished its estrogenicity based on proliferation and gene expression in human breast cancer MCF-7 cells.
TL;DR: Bisphenol A sulfation in human liver cytosols was inhibited by more than 90% by p-nitrophenol and quercetin, a typical substrate and specific inhibitor of phenol sulfotransferase, respectively, indicating that the estrogenicity of bispenol A was abolished through its sulfation catalyzed by a human hepatic thermostable phenol sulfurase.
Journal ArticleDOI
Transient trimethylaminuria related to menstruation
TL;DR: Data is described to support the proposal that menses can be an additional factor causing transient trimethylaminuria in self-reported subjects suffering from malodor and even in healthy women harboring functionally active flavin-containing monooxygenase 3 (FMO3).